Alkem Laboratories · NSE: ALKEM · BSE: 539523
Q1 FY21 results · Apr–Jun 2020
Alkem Laboratories reported revenue from operations of ₹2,003.49 crore (up 8.3% from Q1 FY20) and net profit of ₹423.19 crore (up 126.0% from Q1 FY20) for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,003.49 | 1,849.50 | +8.3% | 2,048.99 | −2.2% |
| Other income | 43.50 | 17.47 | +149.0% | 27.47 | +58.4% |
| Total income | 2,046.99 | 1,866.97 | +9.6% | 2,076.46 | −1.4% |
| Profit before tax | 492.75 | 210.02 | +134.6% | 235.30 | +109.4% |
| Net profit for the period | 423.19 | 187.29 | +126.0% | 191.54 | +120.9% |
| Attributable to shareholders of the company | 422.01 | 185.47 | +127.5% | 188.77 | +123.6% |
| EPS, basic (₹) | 35.30 | 15.51 | +127.5% | 15.79 | +123.6% |
| Net margin (%) | 21.1 | 10.1 | 9.3 |
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,550.85 | 1,498.51 | +3.5% | 1,687.52 | −8.1% |
| Other income | 32.45 | 12.72 | +155.0% | 25.92 | +25.2% |
| Total income | 1,583.30 | 1,511.23 | +4.8% | 1,713.44 | −7.6% |
| Profit before tax | 479.13 | 228.56 | +109.6% | 306.43 | +56.4% |
| Net profit for the period | 426.16 | 210.62 | +102.3% | 271.21 | +57.1% |
| EPS, basic (₹) | 35.64 | 17.62 | +102.3% | 22.68 | +57.1% |
| Net margin (%) | 27.5 | 14.1 | 16.1 |
Consolidated
- Filed with BSE
- 07 Aug 2020, 18:07 IST
- Board meeting
- 07 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Aug 2020, 18:07 IST
- Board meeting
- 07 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE